Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
Identifieur interne : 004E93 ( Main/Exploration ); précédent : 004E92; suivant : 004E94Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
Auteurs : Nadir Syed [États-Unis] ; John Murphy [États-Unis] ; Thomas Zimmerman Jr. [États-Unis] ; Margery H. Mark [États-Unis] ; Jacob I. Sage [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antiparkinson Agents (administration & dosage), Antiparkinson agent, Chemotherapy, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Enteral administration, Female, Fluctuations, Humans, Indication, Infusion, Infusion Pumps, Infusions, Parenteral (instrumentation), Levodopa, Levodopa (administration & dosage), Levodopa (adverse effects), Long term, Male, Middle Aged, Motor Skills (drug effects), Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pump, Route of administration, Treatment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , adverse effects : Levodopa.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- instrumentation : Infusions, Parenteral.
- Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Infusion Pumps, Male, Middle Aged, Treatment Outcome.
Abstract
We report our long‐term experience using enteral levodopa infusions in 22 patients with Parkinson's disease and severe motor fluctuations. Amelioration of intractable dyskinesias was the most important factor that determined whether patients chose to continue using the infusion pump system. Mechanical and physical problems associated with enteral access were the most common reasons for which patients discontinued pump use. Nearly all patients continued to have dramatically increased on time for the duration of follow up, suggesting that technically less‐cumbersome systems that provide continuous dopaminergic stimulation are worthwhile and should be developed.
Url:
DOI: 10.1002/mds.870130222
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003684
- to stream Istex, to step Curation: 003684
- to stream Istex, to step Checkpoint: 003628
- to stream PubMed, to step Corpus: 004452
- to stream PubMed, to step Curation: 004452
- to stream PubMed, to step Checkpoint: 004326
- to stream Ncbi, to step Merge: 004F21
- to stream Ncbi, to step Curation: 004F21
- to stream Ncbi, to step Checkpoint: 004F21
- to stream Main, to step Merge: 007E05
- to stream PascalFrancis, to step Corpus: 003043
- to stream PascalFrancis, to step Curation: 003781
- to stream PascalFrancis, to step Checkpoint: 002F15
- to stream Main, to step Merge: 008039
- to stream Main, to step Curation: 004E93
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease</title><author><name sortKey="Syed, Nadir" sort="Syed, Nadir" uniqKey="Syed N" first="Nadir" last="Syed">Nadir Syed</name></author><author><name sortKey="Murphy, John" sort="Murphy, John" uniqKey="Murphy J" first="John" last="Murphy">John Murphy</name></author><author><name sortKey="Zimmerman Jr, Thomas" sort="Zimmerman Jr, Thomas" uniqKey="Zimmerman Jr T" first="Thomas" last="Zimmerman Jr.">Thomas Zimmerman Jr.</name></author><author><name sortKey="Mark, Margery H" sort="Mark, Margery H" uniqKey="Mark M" first="Margery H." last="Mark">Margery H. Mark</name></author><author><name sortKey="Sage, Jacob I" sort="Sage, Jacob I" uniqKey="Sage J" first="Jacob I." last="Sage">Jacob I. Sage</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:54E3E3ED73F72BBA40CAD37A2EEF4D14317CA23B</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130222</idno><idno type="url">https://api.istex.fr/document/54E3E3ED73F72BBA40CAD37A2EEF4D14317CA23B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003684</idno><idno type="wicri:Area/Istex/Curation">003684</idno><idno type="wicri:Area/Istex/Checkpoint">003628</idno><idno type="wicri:doubleKey">0885-3185:1998:Syed N:ten:years:experience</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9539350</idno><idno type="wicri:Area/PubMed/Corpus">004452</idno><idno type="wicri:Area/PubMed/Curation">004452</idno><idno type="wicri:Area/PubMed/Checkpoint">004326</idno><idno type="wicri:Area/Ncbi/Merge">004F21</idno><idno type="wicri:Area/Ncbi/Curation">004F21</idno><idno type="wicri:Area/Ncbi/Checkpoint">004F21</idno><idno type="wicri:doubleKey">0885-3185:1998:Syed N:ten:years:experience</idno><idno type="wicri:Area/Main/Merge">007E05</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0177456</idno><idno type="wicri:Area/PascalFrancis/Corpus">003043</idno><idno type="wicri:Area/PascalFrancis/Curation">003781</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002F15</idno><idno type="wicri:doubleKey">0885-3185:1998:Syed N:ten:years:experience</idno><idno type="wicri:Area/Main/Merge">008039</idno><idno type="wicri:Area/Main/Curation">004E93</idno><idno type="wicri:Area/Main/Exploration">004E93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease</title><author><name sortKey="Syed, Nadir" sort="Syed, Nadir" uniqKey="Syed N" first="Nadir" last="Syed">Nadir Syed</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick</wicri:cityArea></affiliation></author><author><name sortKey="Murphy, John" sort="Murphy, John" uniqKey="Murphy J" first="John" last="Murphy">John Murphy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Associated Neurologists, Danbury, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Zimmerman Jr, Thomas" sort="Zimmerman Jr, Thomas" uniqKey="Zimmerman Jr T" first="Thomas" last="Zimmerman Jr.">Thomas Zimmerman Jr.</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick</wicri:cityArea></affiliation></author><author><name sortKey="Mark, Margery H" sort="Mark, Margery H" uniqKey="Mark M" first="Margery H." last="Mark">Margery H. Mark</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick</wicri:cityArea></affiliation></author><author><name sortKey="Sage, Jacob I" sort="Sage, Jacob I" uniqKey="Sage J" first="Jacob I." last="Sage">Jacob I. Sage</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-03">1998-03</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="336">336</biblScope><biblScope unit="page" to="338">338</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">54E3E3ED73F72BBA40CAD37A2EEF4D14317CA23B</idno><idno type="DOI">10.1002/mds.870130222</idno><idno type="ArticleID">MDS870130222</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Enteral administration</term><term>Female</term><term>Fluctuations</term><term>Humans</term><term>Indication</term><term>Infusion</term><term>Infusion Pumps</term><term>Infusions, Parenteral (instrumentation)</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Long term</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pump</term><term>Route of administration</term><term>Treatment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Infusions, Parenteral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Infusion Pumps</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Fluctuation motrice</term><term>Indication</term><term>Long terme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Pompe</term><term>Traitement</term><term>Voie administration</term><term>Voie entérale</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term><term>Pompe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report our long‐term experience using enteral levodopa infusions in 22 patients with Parkinson's disease and severe motor fluctuations. Amelioration of intractable dyskinesias was the most important factor that determined whether patients chose to continue using the infusion pump system. Mechanical and physical problems associated with enteral access were the most common reasons for which patients discontinued pump use. Nearly all patients continued to have dramatically increased on time for the duration of follow up, suggesting that technically less‐cumbersome systems that provide continuous dopaminergic stimulation are worthwhile and should be developed.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li><li>New Jersey</li></region></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Syed, Nadir" sort="Syed, Nadir" uniqKey="Syed N" first="Nadir" last="Syed">Nadir Syed</name></region><name sortKey="Mark, Margery H" sort="Mark, Margery H" uniqKey="Mark M" first="Margery H." last="Mark">Margery H. Mark</name><name sortKey="Murphy, John" sort="Murphy, John" uniqKey="Murphy J" first="John" last="Murphy">John Murphy</name><name sortKey="Sage, Jacob I" sort="Sage, Jacob I" uniqKey="Sage J" first="Jacob I." last="Sage">Jacob I. Sage</name><name sortKey="Zimmerman Jr, Thomas" sort="Zimmerman Jr, Thomas" uniqKey="Zimmerman Jr T" first="Thomas" last="Zimmerman Jr.">Thomas Zimmerman Jr.</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:54E3E3ED73F72BBA40CAD37A2EEF4D14317CA23B
|texte= Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |